A massive new network meta-analysis published in JAMA demonstrates that ARBs (alone or combined with calcium channel blockers) are the best-tolerated hypertension medications, with fewer treatment discontinuations due to adverse events than even a placebo.
Links to full study:
Paper · JAMAJAMA articlejamanetwork.com Paper · JAMAJAMA articlejamanetwork.comThe landmark study, which analyzed over 700 short-term clinical trials, highlighted specific tolerability data:
- Top Monotherapy: ARBs as a single drug class were significantly better tolerated than placebos, boasting remarkably low dropout rates.
- Best Combination: The combination of an ARB plus a Calcium Channel Blocker (CCB) was identified as the overall best-tolerated treatment regimen.
- Four of the Top Five: In the study's rankings, ARBs were featured in four out of the five highest-tolerated treatment strategies.
- CCB Monotherapy: In contrast, calcium channel blockers (CCBs) alone were associated with a higher likelihood of side effects that led to patients stopping treatment.
The clinical takeaway is that prescribing ARB-based regimens can drastically improve long-term adherence, making them a top-tier choice when initiating or adjusting high blood pressure treatments.
